

# Kopfschmerzen

## Was gibt es 2004 Neues?

Hans Christoph Diener, Essen\*

### Literatur

- Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. *Cephalalgia* 1988;8(Suppl 7):1–93.
- Olesen J, Bousser M-G, Diener H, Dodick D, et al. for the International Headache Society. The international classification of headache disorders. 2nd edition. *Cephalalgia* 2004;24(Suppl 1):1–160.
- Rasmussen BK. Epidemiology. In: Olesen J, Tfelt-Hansen P, Welch KMA (editors). *The headaches*. New York: Raven Press, 1993: 439–43.
- Ulrich V, Gervil M, Kyvik KO, Olesen J, et al. Evidence of a genetic factor in migraine with aura: a population-based danish twin study. *Ann Neurol* 1999;45:242–6.
- Joutel A, Bousser M, Biouesse V, Labauge P, et al. A gene for familial hemiplegic migraine maps to chromosome 19. *Nat Genet* 1993;5: 40–5.
- Ophoff RA, Terwindt GM, Vergouwe MN, Eijk Rv, et al. Familial hemiplegic migraine and episodic ataxia type-2 are caused by mutations in the Ca<sup>2+</sup> channel gene CACNA4. *Cell* 1996;87:543–52.
- De Fusco M, Marconi R, Silvestri L, Atorino L, et al. Haploinsufficiency of ATP1A2 encoding the Na/K pump alpha2 subunit associated with familial hemiplegic migraine type 2. *Nat Genet* 2003;33:192–6.
- Ophoff RA, Terwindt GM, Frants RR, Ferrari MD. P/Q-type Ca<sup>2+</sup> channel defects in migraine, ataxia and epilepsy. *TIPS* 1998;19: 121–7.
- Moskowitz M, Bolay H, Dalkara T. Deciphering migraine mechanisms: clues from familial hemiplegic migraine genotypes. *Ann Neurol* 2004;55:276–80.
- Vanmolkot K, Kors E, Hottenga J, Terwindt G, et al. Novel mutations in the Na<sup>+</sup>, K<sup>+</sup>-ATPase pump gene ATP1A2 associated with familial hemiplegic migraine and benign familial infantile convulsions. *Ann Neurol* 2003;54: 360–6.
- Chapman K, Szczygielski B, Toth C, Woolfenden A, et al. Pseudomigraine with lymphocytic pleocytosis: a calcium channelopathy? Clinical description of 10 cases and genetic analysis of the familial hemiplegic migraine gene CACNA1A. *Headache* 2003;43: 892–5.
- Wang S, Fuh J, Lu S, Juang K, et al. Migraine prevalence during menopausal transition. *Headache* 2003;43:470–8.
- Winner P, Wasiewski W, Gladstein J, Linder S, for the Pediatric Headache Committee of the American Association for the Study of H. Multicenter prospective evaluation of proposed pediatric migraine revisions to the IHS criteria. *Headache* 1997;37:545–8.
- Winner P, Rothner A, Putnam D, Asgharnejad M. Demographic and migraine characteristics of adolescents with migraine: Glaxo Wellcome clinical trials' database. *Headache* 2003;43:451–7.
- Evans R, Lipton R, Silberstein S. The prevalence of migraine in neurologists. *Neurology* 2003;61:1271–2.
- Kruit M, van Buchem M, Hofman P, Bakkers J, et al. Migraine as a risk factor for subclinical brain lesions. *JAMA* 2004;291:427–34.
- Harno H, Hirvonen T, Kaunisto M, Aalto H, et al. Subclinical vestibulocerebellar dysfunction in migraine with and without aura. *Neurology* 2003;61:1748–52.
- Chang CL, Donaghy M, Poulter N, and World Health Organisation Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Migraine and stroke in young women: case-control study. *BMJ* 1999;318: 13–8.
- Welch KMA, Bousser M-G. Migraine and stroke. In: Olesen J, Tfelt-Hansen P, Welch KMA (editors). *The headaches*. 2nd ed. Philadelphia: Lippincott Williams & Wilkins, 2000: 529–42.
- Diener H, Welch K, Mohr JP. Migraine and stroke. In: Mohr J, Choi D, Grotta J, Wolf P (editors). *Stroke. Pathophysiology, diagnosis and management*. Philadelphia: Churchill Livingstone, 2004.
- Donaghy M, Chang CL, Poulter N, on behalf of the European Collaborators of The World Health Organisation Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Duration, frequency, recency, and type of migraine and the risk of ischaemic stroke in women of childbearing age. *J Neurol Neurosurg Psychiatry* 2002;73:747–50.
- Breslau N, Davis GC. Migraine, major depression and panic disorder: a prospective epidemiologic study of young adults. *Cephalalgia* 1992;12:85–90.
- Breslau N, Schultz LR, Stewart WF, Lipton RB, et al. Headache and major depression. Is the association specific to migraine? *Neurology* 2000;54:308–13.
- Bahra A, Goadsby PJ. The comorbidity of migraine and depression: a review. *Neurology and Psychiatry* 1998;2:23–7.
- Breslau N, Lipton R, Stewart WF, Schultz LR, et al. Comorbidity of migraine and depression: Investigating potential etiology and prognosis. *Neurology* 2003;60:1308–12.
- Lipton RB, Silberstein SD. Neurologic and psychiatric comorbidity with migraine. *Neurology* 1994;44:S1–S47.
- Leniger T, Diener H. Migräne und Komorbidität. In: Diener H (Hrsg.). *Kopfschmerzen*. Stuttgart: Thieme, 2003:58–60.
- Sztajzel R, Genoud D, Roth S, Mermillod B, et al. Patent foramen ovale, a possible cause of symptomatic migraine: a study of 74 patients with acute ischemic stroke. *Cerebrovasc Dis* 2002;13:102–6.
- Carerj S, Narbone M, Zito C, Serra S, et al. Prevalence of atrial septal aneurysm in patients with migraine: an echocardiographic study. *Headache* 2003;43:725–8.
- Diener HC, Hartung E, Chrubasik J, Evers S, et al. for the Study Group. A comparative study of acetylsalicylic acid and metoprolol for the prophylactic treatment of migraine. A randomised, controlled, double-blind, parallel group phase III study. *Cephalalgia* 2001;21: 140–4.
- Leniger T, von den Driesch S, Isbruch K, Diener H, et al. Clinical characteristics of patients with comorbidity of migraine and epilepsy. *Headache* 2003;43:672–7.
- Leniger T, Diener HC, Hufnagel A. Erhöhte zerebrale Erregbarkeit und "spreading depression" Ursachen für eine Komorbidität von Epilepsie und Migräne? *Nervenarzt* 2003;74: 869–74.

Mit Unterstützung des Bundesministeriums für Bildung und Forschung (BMBF) im Rahmen des Kompetenznetzes Kopfschmerz (01EM0117)

\* Diese Übersicht erscheint in leicht modifizierter Version in den Zeitschriften *Aktuelle Neurologie und Arzneimitteltherapie*

Prof. Dr. Hans-Christoph Diener, Universitätsklinik für Neurologie, Hufelandstr 55, 45122 Essen, E-Mail: h.diener@uni-essen.de.

33. The Diclofenac-K/Sumatriptan Migraine Study Group. Acute treatment of migraine attacks: efficacy and safety of a nonsteroidal anti-inflammatory drug, diclofenac-potassium, in comparison to oral sumatriptan and placebo. *Cephalalgia* 1999;19:232–40.
34. Thomas HM, Kudrow DB, Ashford E, Le V, et al. A phase III multicentre, randomised, double-blind, parallel-group study of valdecoxib 40 mg vs placebo in patients with multiple moderate or severe acute migraine headaches with and without aura [Abstract]. *Cephalalgia* 2003;23:697.
35. Diener HC, Reches A, Pascual J, Jansen J-P, et al. on behalf of the Eletriptan and Cafergot Comparative Study Group. Efficacy, tolerability and safety of oral eletriptan and ergotamine plus caffeine (Cafergot) in the acute treatment of migraine: a multicentre, randomised, double-blind, placebo-controlled comparison. *Eur Neurol* 2002;47:99–107.
36. The Multinational Oral Sumatriptan Cafergot Comparative Study Group. A randomized, double-blind comparison of sumatriptan and Cafergot in the acute treatment of migraine. *Eur Neurol* 1991;31:314–22.
37. Charlesworth B, Dowson A, Purdy A, Becker W, et al. Speed of onset and efficacy of zolmitriptan nasal spray in the acute treatment of migraine: a randomised, double-blind, placebo-controlled, dose-ranging study versus zolmitriptan tablet. *CNS Drugs* 2003;17:653–67.
38. Göbel H, Boswell D, Winter PDO, Crisp A. A comparison of the efficacy and tolerability of naratriptan and sumatriptan among migraineurs with a history of frequent (50 % of attacks) headache recurrence [Poster]. VIIIth IHS Congress, Amsterdam, 1997:163–5.
39. Sheftell F, O'Quinn S, Watson C, Pait D, et al. Low migraine headache recurrence with naratriptan: clinical parameters related to recurrence. *Headache* 2000;40:103–10.
40. Tfelt-Hansen P, Teall J, Rodriguez F, Giacobazzo M, et al. on behalf of the Rizatriptan 030 Study Group. Oral rizatriptan versus oral sumatriptan: a direct comparative study in the acute treatment of migraine. *Headache* 1998;38:748–55.
41. Goldstein J, Ryan R, Jiang K, Getson A, et al. and the Rizatriptan Protocol 046 Study Group. Crossover comparison of rizatriptan 5 mg and 10 mg versus sumatriptan 25 and 50 mg in migraine. *Headache* 1998;38:737–47.
42. Tfelt-Hansen P, Ryan RE. Oral therapy for migraine: comparisons between rizatriptan and sumatriptan. A review of four randomized, double-blind clinical trials. *Neurology* 2000;55(Suppl 2):S19–S24.
43. Goadsby PJ, Ferrari MD, Olesen J, Stovner LJ, et al. for the Eletriptan Steering Committee. Eletriptan in acute migraine: a double-blind, placebo-controlled comparison to sumatriptan. *Neurology* 2000;54:156–63.
44. Sandrini G, Färkkilä M, Burgess G, Foster E, et al. for the Eletriptan Steering Committee. Eletriptan vs. sumatriptan. A double-blind, placebo-controlled, multiple migraine attack study. *Neurology* 2002;59:1210–7.
45. Diener H, Ryan R, Sun W, Hettiarachchi J. The 40-mg dose of eletriptan: comparative efficacy and tolerability versus sumatriptan 100 mg. *Eur J Neurol* 2004;11:125–34.
46. Garcia-Ramos G, MacGregor E, Hilliard B, Bordini C, et al. Comparative efficacy of eletriptan vs. naratriptan in the acute treatment of migraine. *Cephalalgia* 2003;23:869–76.
47. Steiner T, Diener H, MacGregor E, Schoenen J, et al. Comparative efficacy of eletriptan and zolmitriptan in the acute treatment of migraine. *Cephalalgia* 2003;23:942–52.
48. Pascual J, Falk R, Docekal R, Prusinski A, et al. Tolerability and efficacy of almotriptan in the long-term treatment of migraine. *Eur Neurol* 2001;45:206–13.
49. Dowson AJ, Massiou H, Lainez JM, Cabarcas X. Almotriptan is an effective and well-tolerated treatment for migraine pain: results of a randomised, double-blind, placebo-controlled clinical trial. *Cephalalgia* 2002;22:453–61.
50. Visser WH, de Vriend RHM, Jaspers N, Ferrari MD. Sumatriptan – nonresponders: a survey in 366 migraine patients. *Headache* 1996;36:471–5.
51. Burstein R, Collins B, Jakubowski M. Defeating migraine pain with triptans: a race against development of cutaneous allodynia. *Ann Neurol* 2004;55:19–26.
52. Burstein R, Jakubowski M. Analgesic triptan action in an animal model of intracranial pain: a race against the development of central sensitization. *Ann Neurol* 2004;55:27–36.
53. Mathew N. Early intervention with almotriptan improves sustained pain-free response in acute migraine. *Headache* 2003;43:1075–9.
54. Mathew N, Schoenen J, Winner P, Muirhead N, et al. Comparative efficacy of eletriptan 40 mg versus sumatriptan 100 mg. *Headache* 2003;43:214–22.
55. Färkkilä M, Olesen J, Dahlof C, Stovner L, et al. Eletriptan for the treatment of migraine in patients with previous poor response or tolerance to oral sumatriptan. *Cephalalgia* 2003;23:463–71.
56. Chia Y, Lim S, Wang S, Cheong Y, et al. Efficacy of eletriptan in migraineurs with persistent poor response to nonsteroidal anti-inflammatory drugs. *Headache* 2003;43:984–90.
57. Mathew N, Hettiarachchi J, Alderman J. Tolerability and safety of eletriptan in the treatment of migraine: a comprehensive review. *Headache* 2003;43:962–74.
58. Christie S, Göbel H, Mateos V, Allen C, et al., Rizatriptan-Ergotamine/Caffeine Preference Study Group. Crossover comparison of efficacy and preference for rizatriptan 10 mg versus ergotamine/caffeine in migraine. *Eur Neurol* 2002;49:20–9.
59. Baos V, Serrano A, Torrecilla M, Bertral C, et al., I-MAX Study Group. Patient-reported benefits of rizatriptan compared with usual non-triptan therapy for migraine in a primary care setting. *Int J Clin Pract* 2003;57:761–8.
60. Schulman E, Dermott K. Sumatriptan plus metoclopramide in triptan-nonresponsive migraineurs. *Headache* 2003;43:729–33.
61. The Subcutaneous Sumatriptan International Study Group. Treatment of migraine attacks with sumatriptan. *N Engl J Med* 1991;325:316–21.
62. Diener HC, for the ASASUMAMIG Study Group. Efficacy and safety of intravenous acetylsalicylic acid lysinate compared to subcutaneous sumatriptan and parenteral placebo in the acute treatment of migraine. A double-blind, double-dummy, randomized, multicenter, parallel group study. *Cephalalgia* 1999;19:581–8.
63. Stillman M, Zajac D, Rybicki L. Treatment of primary headache disorders with intravenous valproate: initial outpatient experience. *Headache* 2004;44:65–9.
64. Goadsby PJ, Edvinsson L, Ekman R. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. *Ann Neurol* 1990;28:183–7.
65. Doods H, Hallermayer G, Wu D, Entzeroth M, et al. Pharmacological profile of BIBN4096BS, the first selective small molecule CGRP antagonist. *Br J Pharmacol* 2000;129:420–3.
66. Olesen J, Diener H, Husstedt IW, Goadsby PJ, et al., for the BIBN 4096 BS Clinical Proof of Concept Study Group. Calcitonin gene-related peptide (CGRP) receptor antagonist BIBN4096BS is effective in the treatment of migraine attacks. *N Engl J Med* 2004;350:1104–10.
67. Eikermann A, Diener HC. Effect of active treatment is lower when using placebo control in clinical trials on acute therapy of migraine. *Cephalalgia* 2003;23:344–7.
68. Reuter U, Sanchez Del Rio M, Carpay J, Boes CJ, et al. for the GSK Headache Masters Program. Placebo adverse events in headache trials: headache as an adverse event of placebo. *Cephalalgia* 2003;23:496–503.
69. Diener HC and die Kommission Leitlinien der Deutschen Gesellschaft für Neurologie (Hrsg.). Leitlinien für Diagnostik und Therapie in der Neurologie. 2. ed. Stuttgart: Thieme, 2003.
70. Brandes J, Saper J, Diamond M, Couch J, et al., MIGR-002 Study Group. Topiramate for migraine prevention: a randomized controlled trial. *JAMA* 2004;291:965–73.
71. Martinez H, Londono O, Cantu-Martinez L, del Carmen Tarin L, et al. Topiramate as an adjunctive treatment in migraine prophylaxis. *Headache* 2003;43:1080–4.
72. Silvestrini M, Bartolini M, Coccia M, Baruffaldi R, et al. Topiramate in the treatment of chronic migraine. *Cephalalgia* 2003;23:820–4.
73. Tronvik E, Stovner L, Helde G, Sand T, et al. Prophylactic treatment of migraine with an angiotensin II receptor blocker: a randomized controlled trial. *JAMA* 2003;289:65–9.
74. Gallai V, Alberti A, Rossi C, Coppola F, et al. An open-label pilot study on the efficacy and tolerability of levetiracetam in the prophylaxis of migraine. *J Headache Pain* 2003;4:92–6.
75. Koseoglu E, Akboyraz A, Soyuer A, Ersoy A. Aerobic exercise and plasma beta endorphin levels in patients with migrainous headache without aura. *Cephalalgia* 2003;23:972–6.

76. Zagami AS. Chronic tension-type headache – rational drug treatment options. *CNS Drugs* 1995;4:90–8.
77. Fogelholm R, Murros K. Tizanidine in chronic tension-type headache: A placebo controlled double-blind cross-over study. *Headache* 1992;32:509–13.
78. Murros K, Kataja M, Hedman C, Havanka H, et al. for the Finnish Sirdalud Study Group. Modified-release formulation of tizanidine in chronic tension-type headache. *Headache* 2000;40:633–7.
79. Shimomura T, Awaki E, Kowa H, Takahashi K. Treatment of tension-type headache with tizanidine hydrochloride: Its efficacy and relationship to the plasma MHPG concentration. *Headache* 1991;31:601–4.
80. Holroyd K, Labus J, O'Donnell F, Cordingley G. Treating chronic tension-type headache not responding to amitriptyline hydrochloride with paroxetine hydrochloride: a pilot evaluation. *Headache* 2003;43:999–1004.
81. Bendtsen L, Jensen R, Olesen J. A non-selective (amitriptyline), but not a selective (citalopram), serotonin reuptake inhibitor is effective in the prophylactic treatment of chronic tension-type headache. *J Neurol Neurosurg Psychiatry* 1996;61:285–90.
82. Torelli P, Jensen R, Olesen J. Physiotherapy for tension-type headache: a controlled study. *Cephalalgia* 2004;24:29–36.
83. Bahra A, May A, Goadsby PJ. Cluster headache: a prospective clinical study with diagnostic implications. *Neurology* 2002;58:354–61.
84. Ekbom K, Monstad I, Prusinski A, Cole JA, et al. Subcutaneous sumatriptan in the acute treatment of cluster headache: a dose comparison study. *Acta Neurol Scand* 1993;88:63–9.
85. Limmroth V, May A, Diener HC. Der Stellenwert von Sumatriptan in der Anfallstherapie der Migräne und des Clusterkopfschmerzes. *Nervenheilkunde* 1996;15:100–8.
86. Van Vliet JA, Bahra A, Martin V, Ramadan N, et al. Intranasal sumatriptan in cluster headache: Randomized placebo-controlled double-blind study. *Neurology* 2003;60:630–3.
87. Lainez M, Pascual J, Pascual A, Santonja J, et al. Topiramate in the prophylactic treatment of cluster headache. *Headache* 2003;43:784–9.
88. Leone M, Dodick D, Rigamonti A, D'Amico D, et al. Topiramate in cluster headache prophylaxis: an open trial. *Cephalalgia* 2003;23:1001–2.
89. Mulder LJ, Spierings EL. Naratriptan in the preventive treatment of cluster headache. *Cephalalgia* 2002;22:815–7.
90. May A, Goadsby PJ. Neuroimaging of cluster headache. In: Olesen J, Tfelt-Hansen P, Welch KMA (editors). *The Headaches*. 2<sup>nd</sup> edition. Philadelphia: Lippincott Williams & Wilkins, 2000:703–8.
91. May A, Bahra A, Büchel C, Frackowiak RSJ, et al. PET and MRA findings in cluster headache and MRA in experimental pain. *Neurology* 2000;55:1328–35.
92. May A, Bahra A, Buchel C, Frackowiak RS, et al. Hypothalamic activation in cluster headache attacks. *Lancet* 1998;352:275–8.
93. Franzini A, Ferroli P, Leone M, Broggi G. Stimulation of the posterior hypothalamus for treatment of chronic intractable cluster headaches: first reported series. *Neurosurgery* 2003;52:1095–101.
94. Leone M, Franzini A, D'Amico D, Grazi L, et al. Stereotactic electrode implant in inferior posterior hypothalamic gray matter to relieve intractable chronic cluster headache: the first reported case. *Neurology* 2001;56(Suppl 3):A218.
95. Dichgans J, Diener HC, Gerber WD, Verspohl EJ, et al. Analgetika-induzierter Dauerkopfschmerz. *Dtsch Med Wochenschr* 1984;109:369–73.
96. Katsarava Z, Fritsche G, Muessig M, Diener HC, et al. Clinical features of withdrawal headache following overuse of triptans and other headache drugs. *Neurology* 2001;57:1694–8.
97. Limmroth V, Katsarava Z, Fritsche G, Przywara S, et al. Features of medication overuse headache following overuse of different acute headache drugs. *Neurology* 2002;59:1011–4.
98. Rozen T. Melatonin as treatment for idiopathic stabbing headache. *Neurology* 2003;61:865–6.
99. Dodick DW, Mosek AC, Campbell JK. The hypnic (“alarm clock”) headache syndrome. *Cephalalgia* 1998;18:152–6.
100. Raskin NH. The hypnic headache syndrome. *Headache* 1988;28:534–6.
101. Sibon I, Ghorayeb I, Henry P. Successful treatment of hypnic headache syndrome with acetazolamide. *Neurology* 2003;61:1157–8.
102. Higgins J, Cousins C, Owler B, Sarkies N, et al. Idiopathic intracranial hypertension: 12 cases treated by venous sinus stenting. *J Neurol Neurosurg Psychiatry* 2003;74:1662–6.